Enhertu Market Report 2026

Enhertu Market Overview

• The Enhertu market growth in the historic period has been driven by increasing prevalence of her2 positive cancers, limitations of conventional chemotherapy • Market expansion is supported by expanding indications for antibody drug conjugates, growth in her2 testing adoption • Growth Driver: Rising Breast Cancer Prevalence Drives Market Growth • Market Trend: Expanding Indications And Advancing Clinical Trials • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

The key promising market opportunities in the enhertu market include: • HER2-Low Metastatic Breast Cancer (Segmentation By By Indication) → Expected gain of $5.75 Billion • HER2-Positive Metastatic Breast Cancer (Segmentation By By Indication) → Expected gain of $1.92 Billion • HER2-Mutant Non-Small Cell Lung Cancer (NSCLC) (Segmentation By By Indication) → Expected gain of $0.82 Billion

What Is Covered Under Enhertu Market?

Enhertu (trastuzumab deruxtecan) is a targeted cancer therapy used to treat adults with HER2-positive breast cancer that is metastatic or cannot be removed by surgery. Enhertu works by combining a monoclonal antibody (trastuzumab) targeting HER2 with a chemotherapy agent (deruxtecan) that disrupts the growth of cancer cells. The main indication for enhertu is her2-positive metastatic breast cancer, her2-low metastatic breast cancer, her2-mutant non-small cell lung cancer (nsclc), her2-positive metastatic gastric cancer. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). The various treatment lines include first-line therapy, second-line therapy, and third-line therapy and are distributed through multiple distribution channels such as hospital pharmacies, specialty pharmacies, and retail pharmacies.

What Is The Enhertu Market Growth Forecast?

The growth in the forecast period can be attributed to expanding indications for antibody drug conjugates, growth in her2 testing adoption, increasing demand for precision cancer therapies, strong oncology research funding, favorable clinical trial outcomes. Major trends in the forecast period include antibody drug conjugate cancer therapies, targeted her2 directed treatments, expansion of precision oncology, rising use of biomarker based cancer care, shift toward advanced line targeted therapies.

What Is The Driver Of The Enhertu Market?

The increasing prevalence of breast cancer is expected to propel the growth of the enhertu market going forward. Breast cancer is a type of cancer that begins in the cells of the breast, often in the milk ducts or lobules, and can spread to other parts of the body. The increasing prevalence of breast cancer is due to a combination of factors, including an aging population, genetic predispositions, lifestyle factors such as poor diet and lack of physical activity, environmental exposures, and improved detection and screening methods. Enhertu provides targeted therapy for breast cancer patients by delivering a potent combination of chemotherapy and HER2-targeted treatment, helping to improve outcomes for those with advanced or metastatic HER2-positive breast cancer. For instance, in September 2023, according to Breast Cancer Now, a UK-based breast cancer charity, approximately 600,000 people in the UK are currently living after a breast cancer diagnosis, a number expected to double to 1.2 million by 2030. Therefore, the increasing prevalence of breast cancer drives the enhertu industry.

How Will The Drivers Impact Growth In The Global Enhertu Market?

• Expanding Label Approvals Across Multiple HER2-Targeted Indications (High) – During the forecast period, the expanding label approvals across multiple HER2-targeted indications are expected to become a key growth driver for the enhertu market by 2030. Regulatory expansion into broader tumor categories is increasing the eligible patient population and strengthening treatment utilization across oncology settings. As clinical development programs continue to validate therapeutic potential across multiple HER2-expressing cancers, healthcare providers are integrating broader targeted treatment pathways into clinical practice. Pharmaceutical companies are therefore increasing focus on lifecycle expansion strategies to maximize therapeutic reach. This expansion across HER2-targeted indications is reinforcing sustained market growth. • Superior Clinical Outcomes Compared to Conventional HER2 Therapies (Medium) – During the forecast period, the superior clinical outcomes compared to conventional HER2 therapies are expected to emerge as a major factor driving the expansion of the enhertu market by 2030. Improved efficacy profiles and stronger clinical performance are influencing physician treatment preferences across oncology practice settings. Enhanced progression management capabilities and durable treatment responses are contributing to broader adoption patterns among eligible patient populations. Clinical differentiation is also strengthening competitive positioning within targeted oncology treatment landscapes. • Rising Global Cancer Burden and Increasing HER2 Biomarker Testing (High) – During the forecast period, the rising global cancer burden and increasing HER2 biomarker testing are expected to act as a key growth catalyst for the enhertu market by 2030. Expanding oncology screening capabilities and growing biomarker assessment utilization are improving identification rates of HER2-expressing tumors across healthcare systems. Diagnostic advancements are enabling more precise patient selection approaches while supporting broader implementation of biomarker-driven treatment strategies. Improvements in cancer detection infrastructure are further strengthening targeted oncology adoption globally.

How Will The Restraints Impact Growth In The Global Enhertu Market?

• High Treatment Costs and Reimbursement Challenges (High) – During the forecast period, the enhertu’s premium pricing structure may create access barriers, particularly in cost-sensitive healthcare systems and emerging markets. Reimbursement negotiations, payer scrutiny regarding cost-effectiveness, and budget constraints among healthcare providers could limit therapy penetration. Pricing pressure may become more prominent as healthcare systems increasingly focus on value-based oncology treatment frameworks. • Safety Concerns Related to Interstitial Lung Disease (ILD) and Adverse Events (Medium) – During the forecast period, the safety monitoring requirements associated with interstitial lung disease and other treatment-related adverse effects could restrain broader clinical adoption. Physicians may exercise caution in patient selection and treatment management due to risks requiring close monitoring protocols. Regulatory emphasis on safety surveillance and potential treatment discontinuations may modestly affect prescribing patterns during the forecast period. • Intensifying Competition from Emerging HER2-Targeted Therapies (High) – During the forecast period, the growing availability of next-generation HER2-targeted therapies is expected to restrain the growth of the Enhertu market. Pharmaceutical companies are actively developing and commercializing innovative antibody-drug conjugates, monoclonal antibodies, bispecific antibodies, and combination treatment regimens targeting HER2-positive cancers. These emerging therapies may offer differentiated efficacy, improved safety profiles, or expanded treatment flexibility in specific patient populations. As treatment guidelines evolve and physicians gain access to a broader range of HER2-directed options, competitive pressures could influence prescribing decisions and market share distribution. This increasing competition may moderate the long-term growth potential of Enhertu across key oncology indications.

Key Players In The Global Enhertu Market

Major companies operating in the enhertu market are AstraZeneca Plc, Daiichi Sankyo Co. Ltd.

Global Enhertu Market Trends and Insights

The key trend in the enhertu market involves conducting clinical trials to broaden its indications for treating various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer, beyond its established application in HER2-positive breast cancer. These clinical trials support the development of Enhertu as a targeted treatment option, showing statistically significant and clinically meaningful improvements in progression-free survival for HR-positive, HER2-low metastatic breast cancer patients in the DESTINY-Breast06 Phase 3 trial, after one or more lines of endocrine therapy. For instance, in April 2024, Daiichi Sankyo, a Japan-based pharmaceutical company, and AstraZeneca plc, a UK-based pharmaceutical company, announced the results of the DESTINY-Breast06 Phase 3 trial for ENHERTU (trastuzumab deruxtecan). The trial demonstrated that ENHERTU significantly improves progression-free survival (PFS) in patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer who have received one or more lines of endocrine therapy. This study is significant as it represents the first time a HER2-directed therapy has shown a clinically meaningful benefit for this specific patient population.

What Are Latest Mergers And Acquisitions In The Enhertu Market?

In November 2024, Daiichi Sankyo, a Japan-based pharmaceutical company, entered into a license agreement with Alteogene for $300 million. With this collaboration, Daiichi Sankyo aims to leverage Alteogen's proprietary technologies to develop a subcutaneous version of Enhertu (fam-trastuzumab deruxtecan-nxki), an antibody-drug conjugate partnered with AstraZeneca, in order to provide a more convenient and potentially less invasive alternative for patients receiving the treatment. Alteogene is a South Korea-based company that develops antibody-drug conjugates.

What Defines the Enhertu Market?

The enhertu market consists of sales of lyophilized powder for injection and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Enhertu Market Report 2026?

The enhertu market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the enhertu industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.